BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 172 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $495,879 | -74.2% | 97,614 | -69.6% | 0.00% | -75.0% |
| Q4 2023 | $1,920,837 | -63.6% | 320,674 | -57.0% | 0.00% | -69.2% |
| Q3 2023 | $5,282,402 | +3704.2% | 746,102 | +3682.7% | 0.01% | – |
| Q2 2023 | $138,857 | -89.0% | 19,724 | -86.9% | 0.00% | -100.0% |
| Q1 2023 | $1,257,464 | -60.6% | 150,775 | -45.7% | 0.01% | -61.5% |
| Q4 2022 | $3,188,467 | +45.3% | 277,741 | +59.5% | 0.01% | +18.2% |
| Q3 2022 | $2,195,000 | -55.4% | 174,167 | -42.5% | 0.01% | -47.6% |
| Q1 2022 | $4,927,000 | +635.4% | 303,008 | +526.5% | 0.02% | +950.0% |
| Q4 2021 | $670,000 | +16.1% | 48,366 | -14.8% | 0.00% | -33.3% |
| Q1 2021 | $577,000 | +249.7% | 56,770 | +156.2% | 0.00% | +200.0% |
| Q4 2020 | $165,000 | +323.1% | 22,155 | +94.3% | 0.00% | 0.0% |
| Q3 2020 | $39,000 | -90.4% | 11,400 | -86.6% | 0.00% | -85.7% |
| Q2 2020 | $405,000 | +131.4% | 84,972 | -3.0% | 0.01% | +75.0% |
| Q1 2020 | $175,000 | -91.8% | 87,573 | -85.9% | 0.00% | -69.2% |
| Q4 2019 | $2,135,000 | +109.1% | 618,943 | +73.7% | 0.01% | +44.4% |
| Q3 2019 | $1,021,000 | +526.4% | 356,421 | +726.7% | 0.01% | +350.0% |
| Q2 2019 | $163,000 | -82.2% | 43,113 | -61.6% | 0.00% | -80.0% |
| Q1 2019 | $914,000 | +139.9% | 112,245 | +137.9% | 0.01% | +150.0% |
| Q4 2018 | $381,000 | -17.5% | 47,190 | -22.1% | 0.00% | -33.3% |
| Q3 2018 | $462,000 | -35.8% | 60,611 | -51.8% | 0.01% | -40.0% |
| Q2 2018 | $720,000 | +109.9% | 125,714 | +92.3% | 0.01% | +42.9% |
| Q3 2017 | $343,000 | +75.9% | 65,389 | +86.8% | 0.01% | +75.0% |
| Q2 2017 | $195,000 | +38.3% | 34,999 | +108.3% | 0.00% | 0.0% |
| Q1 2017 | $141,000 | -37.1% | 16,800 | -52.6% | 0.00% | -55.6% |
| Q4 2016 | $224,000 | +91.5% | 35,425 | -14.0% | 0.01% | 0.0% |
| Q1 2016 | $117,000 | -58.4% | 41,197 | +51.5% | 0.01% | -71.0% |
| Q4 2015 | $281,000 | – | 27,200 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $40,692,000 | 16.07% |
| Fairmount Funds Management LLC | 3,343,107 | $35,370,000 | 8.10% |
| Kynam Capital Management, LP | 936,563 | $9,909,000 | 2.53% |
| Velan Capital Investment Management LP | 225,000 | $2,381,000 | 2.42% |
| ORACLE INVESTMENT MANAGEMENT INC | 603,994 | $6,390,000 | 1.94% |
| TANG CAPITAL MANAGEMENT LLC | 1,200,000 | $12,696,000 | 1.93% |
| MPM BioImpact LLC | 639,089 | $6,762,000 | 1.88% |
| Ghost Tree Capital, LLC | 325,000 | $3,439,000 | 1.79% |
| Sarissa Capital Management LP | 1,390,790 | $14,715,000 | 1.48% |
| Prosight Management, LP | 176,680 | $1,869,000 | 1.47% |